Crinetics Pharmaceuticals, Inc.
Crinetics Pharmaceuticals, Inc. (CRNX): 263 pipeline candidates · 36 upcoming catalysts · ~30 mo cash runway · 276 clinical trials. Updated within the last hour.
BioSniper Score
6-factor signal · derived from public data
29.9 months
D/E 0.09 · 0% dilution
Lead: Phase 3
263 candidates
36 upcoming, next in ~12d
0 buys · 12 sells (180d)
A transparent, data-derived signal for Crinetics Pharmaceuticals, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$3.8B
Cash
$115.1M
Quarterly Burn
$124.7M
Runway
29.9 mo
Revenue
$10.7M
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (263 candidates)
| Drug | Phase |
|---|---|
| 0.4% ZOC2017217 | Phase 2 |
| 2D UC-MSC group | Phase 1 |
| 3D hypoxia-preconditioned UC-MSC group | Phase 1 |
| 4D-150 IVT | Phase 1 |
| 9MW2821 | Phase 2 |
| Abatacept | Phase 3 |
| Abiraterone | Phase 2 |
| Abrupt cessation of semaglutide | Phase 4 |
| Acetylcysteine | Phase 1 |
| ACT500 tablets | Phase 1 |
Showing 10 of 263 candidates. Sign up for full pipeline.
Upcoming Catalysts (36)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.8% historical Phase 3 primary-endpoint success rate (n=362)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.8% historical Phase 3 primary-endpoint success rate (n=362)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.8% historical Phase 3 primary-endpoint success rate (n=362)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.8% historical Phase 3 primary-endpoint success rate (n=362)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.8% historical Phase 3 primary-endpoint success rate (n=362)
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
242
Total value held
$4.32B
| Holder | Shares | Value |
|---|---|---|
| fmr llc | 15,759,799 | $572.4M |
| vanguard capital management llc | 9,347,870 | $339.5M |
| janus henderson group plc | 9,040,502 | $328.5M |
| blackrock, inc. | 8,478,815 | $308.0M |
| farallon capital management llc | 8,338,098 | $302.8M |
| wellington management group llp | 8,157,204 | $296.3M |
| driehaus capital management llc | 6,395,922 | $232.3M |
| vanguard portfolio management llc | 4,638,511 | $168.5M |
| bellevue group ag | 3,280,000 | $119.1M |
| geode capital management, llc | 2,480,763 | $90.1M |
Showing top 10 of 242 institutional holders of Crinetics Pharmaceuticals, Inc.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in Crinetics Pharmaceuticals, Inc.'s pipeline?
Crinetics Pharmaceuticals, Inc. (CRNX) has 263 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Crinetics Pharmaceuticals, Inc.'s lead drug candidate?
Crinetics Pharmaceuticals, Inc.'s most advanced tracked candidate is 0.4% ZOC2017217 (Phase 2) for Age Related Cataracts.
What is Crinetics Pharmaceuticals, Inc.'s next catalyst?
Crinetics Pharmaceuticals, Inc.'s next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: A Multicenter, Randomized, Open-label Phase 3 Study Comparing the Efficacy and Safety of IBI362 Vers" — expected June 30, 2026.
What is Crinetics Pharmaceuticals, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Crinetics Pharmaceuticals, Inc. has approximately 29.9 months of cash runway.
What is Crinetics Pharmaceuticals, Inc.'s market capitalization?
Crinetics Pharmaceuticals, Inc.'s market capitalization is approximately $3.8B.
Get the full picture on Crinetics Pharmaceuticals, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.